RVNC vs. MRSN, STTK, GBIO, NGM, HRTX, DAWN, ABCL, MIRM, PRTA, and COLL
Should you be buying Revance Therapeutics stock or one of its competitors? The main competitors of Revance Therapeutics include Mersana Therapeutics (MRSN), Shattuck Labs (STTK), Generation Bio (GBIO), NGM Biopharmaceuticals (NGM), Heron Therapeutics (HRTX), Day One Biopharmaceuticals (DAWN), AbCellera Biologics (ABCL), Mirum Pharmaceuticals (MIRM), Prothena (PRTA), and Collegium Pharmaceutical (COLL). These companies are all part of the "medical" sector.
Revance Therapeutics (NASDAQ:RVNC) and Mersana Therapeutics (NASDAQ:MRSN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations, community ranking and media sentiment.
Mersana Therapeutics has lower revenue, but higher earnings than Revance Therapeutics. Mersana Therapeutics is trading at a lower price-to-earnings ratio than Revance Therapeutics, indicating that it is currently the more affordable of the two stocks.
Revance Therapeutics has a net margin of -134.10% compared to Mersana Therapeutics' net margin of -352.01%. Revance Therapeutics' return on equity of 0.00% beat Mersana Therapeutics' return on equity.
Revance Therapeutics received 152 more outperform votes than Mersana Therapeutics when rated by MarketBeat users. However, 65.78% of users gave Mersana Therapeutics an outperform vote while only 63.88% of users gave Revance Therapeutics an outperform vote.
97.7% of Revance Therapeutics shares are held by institutional investors. Comparatively, 93.9% of Mersana Therapeutics shares are held by institutional investors. 5.1% of Revance Therapeutics shares are held by company insiders. Comparatively, 11.8% of Mersana Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
In the previous week, Mersana Therapeutics had 1 more articles in the media than Revance Therapeutics. MarketBeat recorded 3 mentions for Mersana Therapeutics and 2 mentions for Revance Therapeutics. Mersana Therapeutics' average media sentiment score of 1.22 beat Revance Therapeutics' score of 0.93 indicating that Mersana Therapeutics is being referred to more favorably in the news media.
Revance Therapeutics presently has a consensus target price of $11.50, indicating a potential upside of 304.93%. Mersana Therapeutics has a consensus target price of $6.29, indicating a potential upside of 169.77%. Given Revance Therapeutics' higher possible upside, equities research analysts plainly believe Revance Therapeutics is more favorable than Mersana Therapeutics.
Revance Therapeutics has a beta of 1.16, indicating that its share price is 16% more volatile than the S&P 500. Comparatively, Mersana Therapeutics has a beta of 1.61, indicating that its share price is 61% more volatile than the S&P 500.
Summary
Mersana Therapeutics beats Revance Therapeutics on 10 of the 18 factors compared between the two stocks.
Get Revance Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RVNC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RVNC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Revance Therapeutics Competitors List
Related Companies and Tools
